All In Biotech

Drug Trial Radar · NCT06162169

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

A Single-center, Non-randomized, Open-lable, Self-controlled Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Nov 25, 2023

Primary completion

Feb 20, 2024

Study completion Feb 20, 2024

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole, rifampicin, and omeprazole in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

  • JAB-21822Drug

    JAB-21822 was administered orally

  • ItraconazoleDrug

    Itraconazole was administered orally

  • OmeprazoleDrug

    Omeprazole was administered orally

  • Midazolam , Rosuvastatin calcium and digoxinDrug

    Midazolam , Rosuvastatin calcium and digoxin was administered orally

  • RifampicinDrug

    Rifampicin was administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed maximum concentrations (Cmax )of JAB-21822Time frame: approximately 10 days
  2. Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of JAB-21822Time frame: approximately 10 days
  3. Area under the concentration versus time curve from dose to infinity (AUC0-∞) of JAB-21822Time frame: approximately 10 days
  4. Observed maximum concentrations (Cmax )of midazolam, rosuvastatin, and digoxinTime frame: approximately 10 days
  5. Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of midazolam, rosuvastatin, and digoxinTime frame: approximately 10 days
  6. Area under the concentration versus time curve from dose to infinity (AUC0-∞) of midazolam, rosuvastatin, and digoxinTime frame: approximately 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.